TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

GLYDO

LIDOCAINE HYDROCHLORIDE
Dermatology Approved 2014-04-28
1
Indication
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2014-04-28
Routes
TOPICAL
Dosage Forms
JELLY

Companies

Active Ingredient: LIDOCAINE HYDROCHLORIDE

GLYDO Approval History

Loading approval history...

What GLYDO Treats

2 indications

GLYDO is approved for 2 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pain
  • Urethritis
Source: FDA Label

GLYDO Boxed Warning

Life-threatening and fatal events in infants and young children Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of Lidocaine Viscous 2% when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, Lidocaine Viscous 2% should generally not be used. For other conditions, the use of the product in patients less than 3 years of age should be limit...

Drugs Similar to GLYDO

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACUVAIL
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Pain
AZITHROMYCIN
AZITHROMYCIN
1 shared
Aurobindo Pharma
Shared indications:
Urethritis
BELBUCA
BUPRENORPHINE HYDROCHLORIDE
1 shared
BDSI
Shared indications:
Pain
BUPRENORPHINE
BUPRENORPHINE
1 shared
WATSON LABS TEVA
Shared indications:
Pain
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
ASPIRIN
1 shared
STEVENS J
Shared indications:
Pain
BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE
1 shared
Hikma
Shared indications:
Pain
BUTORPHANOL TARTRATE PRESERVATIVE FREE
BUTORPHANOL TARTRATE
1 shared
Pfizer
Shared indications:
Pain
BUTRANS
BUPRENORPHINE
1 shared
PURDUE PHARMA LP
Shared indications:
Pain
BYQLOVI
CLOBETASOL PROPIONATE
1 shared
HARROW EYE
Shared indications:
Pain
CALDOLOR
IBUPROFEN
1 shared
CUMBERLAND PHARMS
Shared indications:
Pain
CATAFLAM
DICLOFENAC POTASSIUM
1 shared
AMICI PHARMA
Shared indications:
Pain
COMBOGESIC IV
ACETAMINOPHEN
1 shared
Hikma
Shared indications:
Pain
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
1 shared
INGENUS PHARMS LLC
Shared indications:
Pain
DIFLUNISAL
DIFLUNISAL
1 shared
Teva
Shared indications:
Pain
DIFLUPREDNATE
DIFLUPREDNATE
1 shared
Cipla
Shared indications:
Pain
DILAUDID
HYDROMORPHONE HYDROCHLORIDE
1 shared
Fresenius Kabi
Shared indications:
Pain
DUREZOL
DIFLUPREDNATE
1 shared
Novartis
Shared indications:
Pain
EC-NAPROSYN
NAPROXEN
1 shared
ATNAHS PHARMA US
Shared indications:
Pain
EXPAREL
BUPIVACAINE
1 shared
PACIRA PHARMS INC
Shared indications:
Pain
FLAVOXATE HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE
1 shared
PADAGIS US
Shared indications:
Urethritis
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GLYDO FDA Label Details

Pro

Indications & Usage

Lidocaine is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.

โš ๏ธ BOXED WARNING

WARNING: Life-threatening and fatal events in infants and young children Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of Lidocaine Viscous 2% when it was not administered in strict adherence to the dosing and admi...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.